Orexo AB Announces Dosing of First Patient With OX51 in Phase II Clinical Trial on Prevention of Procedure-Induced Pain
10/30/2012 6:48:57 AM
Swedish specialty pharmaceutical company Orexo today communicated the start of
the dose finding study for OX51 in patients undergoing prostate biopsy. Results
from the study, which is a European study enrolling approximately 200 patients,
will be available during the first half of 2013.
OX51 is a novel breakthrough innovation from Orexo, which has been developed to
meet the fast growing demand for efficient pain management during short-term
surgical and invasive diagnostic procedures. OX51 is a sublingual formulation of
alfentanil, based on the leading sublingual delivery technology developed by
Orexo. The quick onset, short duration, rapid offset and convenient
administration of OX51 make it suitable for prevention of pain during a
multitude of procedures.